EMA Publish List of References Supporting the Assessment of Valeriana officinalis L., radix and Humulus Lupulus L., flos
Full Text Here
The Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.
Abourashed EA, Koetter U, Brattström A. In vitro binding experiments with a valerian, hops and their fixed combination extract (Ze91019) to selected central nervous system receptors. Phytomedicine 2004; 11: 633-638
Balduini W, Cattabeni F. Displacement of [3H]N6-cyclohexyladenosine binding to rat cortical membranes by an hydroalcoholic extract of Valeriana officinalis. Med Sci Res 1989; 17: 639-640
Bos R, Woerdenbag HJ, De Smet PAGM et al. Valeriana species. In: De Smet PGMA, Keller K, Haensel R, Chandler RD (eds.): Adverse effects of herbal drugs. Vol 3, Springer-Verlag Berlin, 1998; 165-180
Brattström A. Wirksamkeitsnachweis von Phytopharmaka am Beispiel einer Hopfen-Baldrian-Kombination. Forsch Komplementärmed 1996; 3: 188-195
Brattström A. Scientific evidence for a fixed extract combination (Ze 91019) from valerian and hops traditionally used as a sleep-induced aid. Wien Med Wochenschr 2007; 157 (13-14): 367-370
Butterweck V, Brattstroem A, Grundmann O, Koetter U. Hypothermic effects of hops are antagonized with the competitive melatonin receptor antagonist luzindole in mice. J Pharm Pharmacol 2007; 59: 549-552
Cavadas C, Araújo I, Cotrim MD, Amaral T, Cunha AP, Macedo T, Fontes Ribeiro C. In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABA-A receptor in rat brain. Arzneim.-Forsch./Drug Res 1995; 45/II (7): 753-755
Coxeter PD, Schluter PJ, Eastwood HL, et al. Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-I trials. Complementary Therapies in Medicine 2003; 11: 215-222
Dorn M. Efficacy and tolerability of valerian versus oxazepam in non-organic and non-psychiatric insomnias: a randomized, double-blind, clinical, comparative study. Komplementaermedizin und Klassische Naturheilkunde 2000; 7: 79-84
Estrada J, Gozala F, Cecchini L, Casquette E. Contact urticaria from hops (Humulus lupulus) in a patient with previous urticaria-angioedema from peanut, chestnut, and banana. Contact Dermat 2002; 46: 127
Flesch P. Hopfen-Baldrian-Kombination als Benzodiazepin-Ersatz? Geriatrie Praxis 1, 1997 (suppl.) 21-23
Füssel A, Wulf A, Brattström, A. Effect of a fixed valerian-hop extract combination (ZE91019) on sleep polygraphy in patients with non-organic insomnia: a pilot study. Eur J Med Res 2000; 18 (5): 385-390
Gerhauser C, Frank N. Xanthohumol, a new all-rounder? Molec Nutr & Food Res 2005; 49 (9): 821-823
Göggelmann W, Schimmer O. Mutagenic activity of phytotherapeutical drugs. In: Knudsen I, editor. Genetic Toxicology of the Diet. New York, Alan R. Liss, 1986; 63-72
Grundmann O, Brattström A, Koetzer U, Butterweck V. Hypothermic effects of hops could antagonise with the competitive melatonin receptor antagonist luzindole. Planta Medica 2006; 72 (11): 1065, 281
Hendriks H, Bos R, Woerdenbag HJ, Joster AS. Central nervous depressant activity of valerenic acid in the mouse. Planta Med 1985; 51: 28-31
Jacobs BP, Bent S, Tice JA, et al. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Medicine 2005; 84: 197-207
Kamm-Kohl AV, Jansen W, Brockmann P. Moderne Baldriantherapie gegen nervöse Störungen im Senium. Med Welt 1984; 35: 1450-1454
Koetter U, Schrader E, Käufeler R, Brattström A. A randomized, double-blind, placebo-controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder. Phytoher Res 2007; 21: 847-851
Lataster MJ, Brattström A. Die Behandlung von Patienten mit Schlafstörungen. Wirksamkeit und Verträglichkeit von Baldrian-Hopfen-Dragees. Notabene Medici 1996; 4: 182-185
Leathwood PD, Chauffard F, Heck E, Munoz-Box R. Aqueous extracts of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav 1982; 17: 65-71
Mennini T, Bernasconi P, Bombardelli E, Morazzoni P: In vitro study on the interactions of extracts and pure compounds from Valeriana officinalis roots with GABA, benzodiazepine and barbiturate receptors in rat brain. Fitoterapia 1993; 64 (4): 291-300
Milligan S, Kalita J, Pocock V, Heyerick A, De Cooman L, Rong H, De Keukeleire D. Oestrogenic activity of the hop phyto-oestrogen, 8-prenylnaringenin. Reproduction 2002; 123: 235-242
Morin CM, Koetter U, Bastien C, Wane JC, Wooter V. Valerian-hops combination and diphenhydramine for treating insomnia: a randomised placebo-controlled clinical trial. Sleep 2005; 28 (11): 1465-1471
Mueller-Limmroth W, Ehrenstein W. Experimental studies of the effects of Seda-Kneipp on the sleep of sleep disturbed subjects: implications of the treatment of different sleep disturbances. Med Klin 1977; 72: 1119-1125
Mueller CE, Schumacher R, Brattström A, Abourashed EA, Koetter E. Interactions of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors. Life Sciences 2002; 71 (16): 1939-1949
Notter D, Brattström A, Morandell D, Polasek W. Wirksamkeit und Sicherheit eines Baldrian-Hopfen-Kombinationspräparates bei verschiedenen Schlafstörungen. Phytotherapie 2003; 3: 9-12
Ortiz JG, Nieves-Natal J, Chavez P. Effects of Valeriana officinalis extracts on [3H]flunitrazepam binding, synaptosomal [3H]GABA uptake and hippocampal [3H]GABA relase. Neurochem Res 1999; 24: 1373-1378
Rodenbeck A, Hajek G. Polysomnographische Pilotstudie zur Wirkung von Hopfen/Baldrian auf den Schlaf von Patienten mit primärer Insomnie. Eine doppelblinde, randomisierte, placebokontrollierte Studie im Schlaflabor 1998, Study Report MI 9221
Romero-Jimenez M. et al. Genotoxicity and antigenotoxicity of some traditional medicinal herbs. Mut Res 2005; 147-155.
Rücker G, Tautges J, Sieck A, Wenzl H,, Graf E. Untersuchungen zur Isolierung und pharmakodynamischen Aktivität des Sesquiterpens Valeranon aus Nardostachys jatamansi DC. Arzneim.-Forsch./Drug Res 1978; 28/I (1): 7-13
Schellenberg A, Sauer S, Abourashed EA, Koetter U, Brattström A. The fixed combination of valerian and hops (Ze91019) acts via a central adenosine mechanism. Planta Med 2004; 70: 694-697
Schmitz M, Jäckel M. Comparative study for assessing quality of life of patients with exogenous sleep disorders (temporary sleep onset and sleep interruption disorders) treated with a hops-valerian preparation and a benzodiazepine drug. Wien Med Wochenschr 1998; 148: 291-298
Stevens JF, Page JE. Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochem 2004; 65: 1317-1330
Vonderheid-Guth B, Iodora A, Brattström A, Dimpfel W. Pharmacodynamic effects of valerian and hops extract combination (Ze 91019) on the quantitative-topographical EEG in healthy volunteers. Eur J Med Res 2000; 5: 139-144
Von Skramlik E. Über die Giftigkeit und Verträglichkeit von ätherischen Ölen. Pharmazie 1959; 14: 435-445
Vorbach EU, Goertelmeyer R, Brüning J. Therapie von Insomnien. Wirksamkeit und Verträglichkeit eines Baldrianpräparates. Psychopharmakontherapie 1996; 3: 109-115
Wegener T. Phytopharmaka zur Anxiolyse. Zur Wirkung einer Kombination von Baldrian und Hopfen bei Angstzuständen. Dt Apoth Ztg 2003; 143: 618-625
Yuan CH, Mehendale S, Yiao Y, et al: The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Anal 2004; 98: 353-358
Ziegler G, Ploch, Miettinen-Baumann A, Colle W. Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia – a randomiazed, double-blind, comparative clinical study. Eur J Med Res 2002; 7: 480-486
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
